176 related articles for article (PubMed ID: 36284040)
1. Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
Ghezzi C; Perez S; Ryan K; Wong A; Chen BY; Damoiseaux R; Clark PM
Mol Imaging Biol; 2023 Jun; 25(3):541-553. PubMed ID: 36284040
[TBL] [Abstract][Full Text] [Related]
2. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
3. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Nogová L; Boellaard R; Kobe C; Hoetjes N; Zander T; Gross SH; Dimitrijevic S; Pellas T; Eschner W; Schmidt K; Bangard C; Hayes W; Thomas RK; Dietlein M; Giaccone G; Hoekstra OS; Lammertsma AA; Wolf J
J Nucl Med; 2009 Nov; 50(11):1815-9. PubMed ID: 19837761
[TBL] [Abstract][Full Text] [Related]
5. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
6. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Benz MR; Herrmann K; Walter F; Garon EB; Reckamp KL; Figlin R; Phelps ME; Weber WA; Czernin J; Allen-Auerbach MS
J Nucl Med; 2011 Nov; 52(11):1684-1689. PubMed ID: 22045706
[TBL] [Abstract][Full Text] [Related]
7. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
8. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
9. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
10. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
11. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
12. Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
Koizumi T; Fukushima T; Gomi D; Kobayashi T; Sekiguchi N; Mamiya K; Tateishi K; Katou A; Oguchi K
Med Oncol; 2017 Sep; 34(10):169. PubMed ID: 28864950
[TBL] [Abstract][Full Text] [Related]
13. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
14. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
Su H; Bodenstein C; Dumont RA; Seimbille Y; Dubinett S; Phelps ME; Herschman H; Czernin J; Weber W
Clin Cancer Res; 2006 Oct; 12(19):5659-67. PubMed ID: 17020967
[TBL] [Abstract][Full Text] [Related]
15. Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Cook GJ; O'Brien ME; Siddique M; Chicklore S; Loi HY; Sharma B; Punwani R; Bassett P; Goh V; Chua S
Radiology; 2015 Sep; 276(3):883-93. PubMed ID: 25897473
[TBL] [Abstract][Full Text] [Related]
16. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
17. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549.
Ishino S; Miyake H; Vincent P; Mori I
Ann Nucl Med; 2015 Aug; 29(7):613-20. PubMed ID: 26014721
[TBL] [Abstract][Full Text] [Related]
19. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
Bengtsson T; Hicks RJ; Peterson A; Port RE
J Nucl Med; 2012 Apr; 53(4):530-7. PubMed ID: 22414632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]